/PRNewswire/ SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing novel immunotherapies for infectious diseases and their.
Zhaoke Ophthalmology of Hong Kong acquired China/Southeast Asia rights for two eyedrop candidates designed to improve near vision from Seattle’s Visus Therapeutics in a $130 million deal.